<< see all grants
Programme for:institutions
What can be funded:

R+D Works

Deadline for submitting the proposals:01/12/2021 - 17/02/2022
Published by:Narodowe Centrum Badań i Rozwoju NCBR

National Centre for Research and Development


French National Research Agency (ANR), 50 Avenue Daumesnil, 75012 Paris, France

Monika Frenzel, Michael Joulie

Tel. 33 173548332

Tel. 33 180488357

E-mail: ERAPerMed@agencerecherche.fr

Strona www: https://erapermed.isciii.es/

Marcin Chmielewski

Tel. 22 39 07 109

Tel. 48 571 226 666

E-mail: marcin.chmielewski@ncbr.gov.pl


With its fifth transnational call (non-cofunded by the EC), ERA PerMed aims to foster research in prevention in personalised medicine. The overarching goal of the call is the development of tailor-made strategies for prevention of disease and disease progression, at three different levels:

i. preventive measures decreasing the rate of incidence (primary prevention),
ii. early detection to increase the efficacy of a preventive therapy, even before symptoms are developed (secondary prevention), and
iii. interventions preventing disease recurrence or improving patients’ care and quality of life (tertiary prevention).

Research on prevention from over-treatment or overmedicalisation in primary, secondary and tertiary personalised preventive approaches is optional and could be part of research proposals, if applicable.

The clinical relevance of the proposed PM approach needs to be convincingly demonstrated.

The overall objectives of the ERA PerMed call are to:

  • Support translational research projects in the field of personalised medicine;

  • Encourage and enable interdisciplinary collaborations towards implementation of PM, in combining pre-clinical or clinical research with bio-informatics components as well as ELSA research or implementation research, including health economics;

  • Encourage collaboration between academia (research teams from universities, higher education institutions, public research institutions, research centres), clinical/public health research (research teams from hospital/ public health, healthcare settings and other healthcare organisations), private partners e.g. SMEs (small and medium-sized enterprises) as well as policy makers, regulatory/HTA agencies and patient organisations.

As Personalised Medicine is non-disease-specific, but rather an overall approach that can be adopted and adapted to a multiplicity of medical conditions, research projects in every disease entity are encouraged. The involvement of partners with the respective expertise in the consortium is required.

[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

More information:https://erapermed.isciii.es/joint-calls/joint-transnational-call-2022/



ERA PerMed is an ERA-NET Cofund, supported by 32 partners of 23 countries and cofunded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 33 funding organisations have agreed to launch the fifth Joint Transnational Call for collaborative innovative research projects in PM. This represents the fourth additional call non-cofunded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals. The available budget for this call is 29 Mio € (approx.).

  • Opening of online submission tool1st December 2021

  • Submission deadline for pre-proposals: 17 February 2022 (17:00 CET)

  • Submission deadline for invited full-proposals: 14 June 2022 (17:00 CET)

more info :  https://www.gov.pl/web/ncbr/era-permed-v-konkurs-2022


Research field